Phospho-ITGB3 (Tyr785) Antibody

What experimental applications are appropriate for Phospho-ITGB3 (Tyr785) antibodies?

Phospho-ITGB3 (Tyr785) antibodies are validated for multiple research applications, with specific dilution recommendations for each technique. Based on manufacturer specifications, these antibodies are suitable for Western Blot (1:500-1:2000), ELISA (1:2000-20000), Immunohistochemistry on paraffin-embedded sections (IHC-P, 1:50-200), and Immunofluorescence/Immunocytochemistry (IF/ICC, 1:50-300) . While applications may vary between manufacturers, these core techniques represent the primary validated uses for detecting endogenous levels of Integrin Beta 3 protein specifically when phosphorylated at Y785 .

What is the significance of Tyr785 phosphorylation in ITGB3 function?

Tyr785 phosphorylation of ITGB3 occurs primarily in response to thrombin-induced platelet aggregation and is likely involved in outside-in signaling pathways . The phosphorylation state at this residue is functionally significant because a peptide (AA 740-762) within ITGB3 is capable of binding to growth factor receptor-bound protein 2 (GRB2) only when both Tyr-773 and Tyr-785 are phosphorylated . Additionally, this phosphorylation event works in coordination with other modifications, as phosphorylation of Thr-779 inhibits SHC binding . These molecular interactions make Tyr785 phosphorylation a critical regulatory point in ITGB3-mediated signaling cascades.

How should Phospho-ITGB3 (Tyr785) antibodies be stored to maintain reactivity?

For optimal antibody performance, manufacturers consistently recommend storing Phospho-ITGB3 (Tyr785) antibodies at -20°C for up to 1 year from the date of receipt . The antibodies are typically formulated in PBS containing 50% glycerol, 0.5% BSA, and 0.02% sodium azide as preservatives . To maintain antibody integrity, it's essential to avoid repeated freeze-thaw cycles by preparing suitable aliquots upon receipt . For short-term storage and frequent use (up to one month), some manufacturers suggest 4°C storage to minimize freeze-thaw damage .

How can I confirm the specificity of Phospho-ITGB3 (Tyr785) antibody in my experimental system?

Confirming antibody specificity requires multiple validation approaches:

• Phospho-peptide blocking: Western blot analysis with lysates from HeLa, HepG2, and HUVEC cells can be performed alongside a control where the antibody is pre-incubated with the phospho-peptide immunogen . The disappearance of signal in the blocked lane confirms phospho-specificity.

• Phospho-ELISA validation: Compare antibody binding between the phosphorylated target peptide and the corresponding non-phosphorylated peptide using ELISA to verify phospho-specific recognition .

• Phosphorylation-inducing treatments: Compare samples with and without treatments known to induce ITGB3 Tyr785 phosphorylation (e.g., thrombin stimulation for platelet samples) .

• siRNA knockdown: Transfect cells with siRNA targeting ITGB3 (e.g., siRNA-ITGB3 corresponding to human ITGB3 at nucleotides 701-721) and confirm signal reduction in Western blot or other detection methods.

What cell types are most appropriate for studying ITGB3 Tyr785 phosphorylation?

Based on research literature and antibody validation studies, several cell types demonstrate detectable levels of phosphorylated ITGB3 (Tyr785):

• Platelet-derived cells: As ITGB3 forms the integrin alpha-IIb/beta-3 complex (platelet fibrinogen receptor) in platelets, these cells naturally express high levels of ITGB3 and exhibit thrombin-induced phosphorylation at Tyr785 .

• Endothelial cells: HUVEC cells have been used for validation of Phospho-ITGB3 (Tyr785) antibodies in Western blot applications , indicating detectable expression levels.

• Cancer cell lines: HeLa cells (cervical cancer) and HepG2 cells (liver cancer) have been successfully used for antibody validation . Additionally, colorectal cancer cell lines like SW480 and SW620 have demonstrated functional roles for phosphorylated ITGB3 in migration and invasion processes .

• Cell lines with reactive oxygen species (ROS) treatment: Research indicates that ROS treatment can upregulate ITGB3 expression in colorectal cancer cells, potentially affecting phosphorylation status .

How can Phospho-ITGB3 (Tyr785) antibodies be used in cell-based ELISA applications for high-throughput screening?

Cell-based ELISA provides a quantitative approach for measuring phosphorylation levels directly in cultured cells:

• Assay principle: Cells are fixed and permeabilized in multi-well plates, allowing for direct measurement of phosphorylated ITGB3 without the need for cell lysis, protein extraction, or gel electrophoresis .

• Normalization strategies: Multiple normalization methods can be employed:

  • Using anti-GAPDH antibody as an internal positive control

  • Crystal Violet whole-cell staining to normalize for cell density

  • Parallel detection with total ITGB3 antibody to calculate phosphorylation-to-total protein ratios

• Sensitivity considerations: The assay typically requires >5000 cells/well for reliable detection and can detect changes in phosphorylation status following various treatments, inhibitors (e.g., siRNA, chemical inhibitors), or activators.

• Quantification approach: The assay uses HRP-conjugated secondary antibodies that catalyze a colorimetric reaction upon substrate addition, allowing for plate reader-based quantification .

What are the key considerations for using phospho-flow cytometry to analyze ITGB3 Tyr785 phosphorylation in heterogeneous cell populations?

Phospho-flow cytometry enables single-cell analysis of phosphorylation events across different cell subpopulations:

• Cell preparation: Careful fixation and permeabilization protocols are essential for preserving phosphorylation states while allowing antibody access to intracellular epitopes .

• Stimulation dynamics: Consider both in vitro and in vivo stimulation approaches when analyzing phosphorylation kinetics. Research shows that phosphorylation events can be early and transient, requiring precise timing for detection .

• Multiparameter analysis: Combine Phospho-ITGB3 (Tyr785) detection with surface markers to identify specific cell subpopulations exhibiting differential phosphorylation responses.

• Controls: Include both positive controls (stimulated samples with known phosphorylation induction) and negative controls (phosphatase-treated samples or blocking with competing phosphopeptides) .

• Quantification: Report results as fold change in median fluorescence intensity compared to unstimulated controls or as percentage of phospho-positive cells within defined populations.

How does ITGB3 Tyr785 phosphorylation contribute to cancer cell migration and invasion?

Research indicates several mechanisms linking ITGB3 Tyr785 phosphorylation to cancer progression:

• ROS-mediated upregulation: Reactive oxygen species (ROS) markedly upregulate expression of ITGB3, which promotes an aggressive phenotype in cancer cells (e.g., SW480 colorectal cancer cells), with concomitant upregulation of STMN1 (Stathmin-1) .

• Signal transduction pathways: The phosphorylation of ITGB3 at Tyr785 enables formation of protein complexes through interactions with adaptor proteins like GRB2, activating downstream signaling cascades .

• PI3K-Akt-mTOR pathway: Research has identified that STMN1 expression and the PI3K-Akt-mTOR pathway are involved in ROS-induced and ITGB3-mediated migration and invasion of colorectal cancer cells .

• Functional validation: Knockdown of ITGB3 expression using siRNA mitigates the migratory and invasive potential of cancer cells (e.g., SW620 cells or H₂O₂-treated SW480 cells), accompanied by downregulated expression of STMN1 .

What experimental approaches can determine if integrin αvβ3 or αIIbβ3 heterodimers are specifically involved in Tyr785 phosphorylation-dependent functions?

To distinguish between different integrin heterodimers containing ITGB3:

• Co-immunoprecipitation: Use antibodies against ITGAV (integrin αv) or ITGA2B (integrin αIIb) to pull down complexes, followed by Western blotting with Phospho-ITGB3 (Tyr785) antibody to determine which α subunit associates with phosphorylated β3.

• Cell type selection: Use cell types with differential expression of α subunits (e.g., platelets primarily express αIIbβ3, while many other cell types express αvβ3) .

• Heterodimer-specific blocking antibodies: Apply antibodies that specifically recognize and block αvβ3 or αIIbβ3 heterodimers, then measure functional outcomes dependent on Tyr785 phosphorylation.

• α subunit knockdown/knockout: Use siRNA or CRISPR/Cas9 to reduce expression of specific α subunits and determine effects on ITGB3 Tyr785 phosphorylation and downstream functions.

• RGD peptide competition: Use RGD-containing peptides that preferentially bind to either αvβ3 or αIIbβ3 to competitively inhibit specific heterodimer functions .

What are the potential causes and solutions for high background when using Phospho-ITGB3 (Tyr785) antibodies in immunohistochemistry?

High background in IHC can result from several factors:

• Antibody concentration: The recommended dilution range for IHC-P is 1:50-200 . Excessive antibody concentration can cause non-specific binding. Solution: Perform a titration series to determine optimal dilution.

• Antigen retrieval conditions: For Phospho-ITGB3 (Tyr785) IHC, Tris-EDTA buffer at pH 9.0 has been validated for antigen retrieval . Solution: Compare different antigen retrieval methods (heat-induced vs. enzymatic) and buffers.

• Blocking efficiency: Inadequate blocking can lead to non-specific binding. Solution: Increase blocking time or concentration, or try alternative blocking reagents like BSA, normal serum, or commercial blocking solutions.

• Fixation artifacts: Overfixation can cause high background. Solution: Optimize fixation time and conditions, or test samples fixed under different protocols.

• Endogenous peroxidase or phosphatase activity: If using enzyme-based detection systems. Solution: Include appropriate quenching steps (e.g., H₂O₂ treatment for peroxidase).

How can discrepancies between Western blot and immunofluorescence data with Phospho-ITGB3 (Tyr785) antibodies be addressed?

When faced with discrepancies between techniques:

• Epitope accessibility differences: The phospho-epitope may be differentially accessible in native (IF) versus denatured (WB) states. Solution: Test alternative fixation/permeabilization methods for IF or different sample preparation approaches for WB.

• Phosphatase activity: Phosphorylation can be lost during sample preparation. Solution: Include phosphatase inhibitors throughout all steps of sample preparation and ensure cold temperature maintenance.

• Specificity validation: Perform blocking experiments with competing phosphopeptides in both techniques to confirm signal specificity .

• Antibody clone differences: Different antibody clones may perform differently across applications. Solution: Test multiple antibody clones if available or validate the primary antibody in the specific application using appropriate controls.

• Expression level threshold: Western blot may detect bulk changes while IF provides spatial information but may have different detection thresholds. Solution: Enhance signal amplification for the less sensitive technique or use complementary approaches like proximity ligation assay.